Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

423
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

493
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
493
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

616
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
616
Angina IV: Management01:26

Angina IV: Management

441
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
441
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smartphone Ownership Among Cardiology Inpatients Pre-COVID-19 and Post-COVID-19 Pandemic: Secondary Analysis of Randomized Controlled Trials.

JMIR cardio·2026
Same author

Is Aspirin Still Indispensable After PCI-Rethinking Dual Antiplatelet Therapy in Contemporary Practice.

Journal of cardiovascular development and disease·2026
Same author

Prospective Validation of the MIRACLE<sub>2</sub> Score for Early Neurological Stratification After Out-of-Hospital Cardiac-Arrest: The GLOBAL-MIRACLE Registry.

Circulation. Cardiovascular interventions·2026
Same author

ECG-Adapt: A Novel Framework for Robust Electrocardiogram Classification Across Diverse Populations and Recording Conditions.

IEEE transactions on bio-medical engineering·2026
Same author

Impact of Coronary Function Testing on Symptoms and Quality of Life in Patients with Coronary Microvascular Dysfunction: Meta-Analysis of Randomised Controlled Trials.

Journal of clinical medicine·2025
Same author

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Direct Oral Anticoagulants Against Warfarin for Left Ventricular Thrombus Resolution.

Journal of clinical medicine·2025

Related Experiment Video

Updated: Apr 15, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K

Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs.

Maggie He1,2, Joseph Magdy1, Maryam Aziz3

  • 1Yorkshire Heart Centre, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds LS1 3EX, UK.

Journal of Clinical Medicine
|April 14, 2026
PubMed
Summary

Shorter dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) reduces bleeding risk. Three-month DAPT followed by ticagrelor monotherapy is a safe, effective option for select patients, improving personalized treatment strategies.

Keywords:
P2Y12 inhibitorabbreviated DAPTacute coronary syndromebleeding riskdual antiplatelet therapyrisk stratification

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Related Experiment Videos

Last Updated: Apr 15, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.4K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dual antiplatelet therapy (DAPT) for 12 months is standard after acute coronary syndrome (ACS).
  • Emerging data suggest shorter DAPT durations may lower bleeding risk without impacting ischemic outcomes in certain patients.

Purpose of the Study:

  • To review recent evidence on abbreviated DAPT strategies post-ACS with percutaneous coronary intervention (PCI).
  • To evaluate the safety and efficacy of reduced DAPT durations compared to standard therapy.

Main Methods:

  • Synthesis of randomized controlled trials, meta-analyses, and guideline updates from 2023-2025.
  • Analysis of studies evaluating DAPT durations of 1, 3, or 6 months post-ACS/PCI.

Main Results:

  • Immediate aspirin withdrawal increased stent thrombosis (NEO-MINDSET, STOPDAPT-3).
  • One-month DAPT with ticagrelor monotherapy reduced bleeding (ULTIMATE-DAPT, T-PASS).
  • Three-month DAPT showed consistent safety, with significant bleeding reduction (TWILIGHT). Clopidogrel monotherapy increased myocardial infarction risk (STOPDAPT-2 ACS).

Conclusions:

  • Abbreviated DAPT strategies provide personalized alternatives to 12-month therapy.
  • Three-month DAPT followed by ticagrelor monotherapy is a supported strategy for selected ACS patients.
  • Risk stratification and patient factors are crucial for guiding DAPT duration.